Ulf Grawunder is an experienced Swiss Life-Science entrepreneur with over 10 years experience in the therapeutic antibody development industry. With NBE-Therapeutics, he has recently founded his second Swiss Biotech company and is leading NBE-Therapeutics as its CEO since June 2012.
Ulf Grawunder has invented two new patent-pending technologies at NBE-Therapeutics that allow the company to develop most highly innovative antibody-based drugs, including next-generation antibody drug conjugates (ADCs) for the therapy of cancer. Before that, Ulf Grawunder co-founded the Swiss Biotech company 4-Antibody, recently sold to U.S.-based Agenus (AGEN), where since 2004 he served as founding CEO and after 2006 assumed the role of CSO. During his tenure at 4-Antibody, Ulf Grawunder raised about CHF 50 million capital for the company, secured two pharma/biotech collaborations with Boehringer Ingelheim, Germany, and Human Genome Sciences, U.S.A. and grew the company to 50 employees.
Ulf Grawunder is serving on various Boards of non-profit and for-profit life-science organizations and is vice-president and Board member of the Swiss Biotech Association. Ulf Grawunder holds a PhD in Cell Biology from the University of Basel, for work on early B cell development performed at the Basel Institute for Immunology. In addition, Ulf Grawunder holds a Diploma in Technology Entrepreneurship from the Entrepreneur and Business School in St. Gallen, Switzerland (HSG=Hochschule St. Gallen).